Teresa L Kauf

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry
    Teresa L Kauf
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 151:206-12. 2006
  2. ncbi The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period
    Ravi Jhaveri
    Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, NC 27705, USA
    J Pediatr 148:353-8. 2006
  3. ncbi Factors influencing the participation of gastroenterologists and hepatologists in clinical research
    Anouk T Dev
    Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Health Serv Res 8:208. 2008
  4. ncbi Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation
    Jasmina I Radeva
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Clin Transplant 19:122-9. 2005
  5. ncbi Trends in health care resource use for hepatitis C virus infection in the United States
    William C Grant
    Center for Clinical and Genetic Economics, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 42:1406-13. 2005
  6. ncbi Cost-utility analysis of rimonabant in the treatment of obesity
    Christian Hampp
    Pharmacy Health Care Administration, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Value Health 11:389-99. 2008

Collaborators

Detail Information

Publications6

  1. ncbi The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry
    Teresa L Kauf
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 151:206-12. 2006
    ..We sought to characterize resource use and cost of initial hospitalization for AMI in 9 countries and compare the contribution of length of stay (LOS) and procedure use to cost...
  2. ncbi The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period
    Ravi Jhaveri
    Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, NC 27705, USA
    J Pediatr 148:353-8. 2006
    ..To quantify the burden of pediatric hepatitis C virus (HCV) disease over the coming decade...
  3. ncbi Factors influencing the participation of gastroenterologists and hepatologists in clinical research
    Anouk T Dev
    Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Health Serv Res 8:208. 2008
    ..We examined factors that influence the participation of gastroenterologists and hepatologists in clinical research...
  4. ncbi Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation
    Jasmina I Radeva
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Clin Transplant 19:122-9. 2005
    ..Longer follow-up and the cost of everolimus are required to fully evaluate the cost-effectiveness of everolimus vs. azathioprine in post-transplant maintenance...
  5. ncbi Trends in health care resource use for hepatitis C virus infection in the United States
    William C Grant
    Center for Clinical and Genetic Economics, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 42:1406-13. 2005
    ..In conclusion, as patients continue to age and disease burden progresses, suboptimal decisions regarding HCV treatments will bring increasing opportunity costs for the health care system and society...
  6. ncbi Cost-utility analysis of rimonabant in the treatment of obesity
    Christian Hampp
    Pharmacy Health Care Administration, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Value Health 11:389-99. 2008
    ..To estimate the incremental cost-utility ratio (ICUR) of rimonabant 20 mg/day in the treatment of obesity from a third-party payer's perspective...